Summary
Background: The burden of healthcare costs has substantially risen in the last few decades. One possible contributing factor to this increase are the diagnostic approaches for venous thromboembolism (VTE) using only imaging to exclude a diagnosis of VTE.
Objective: To demonstrate cost minimization in the diagnosis of VTE by comparing standalone imaging (computed tomography pulmonary angiography and compression ultrasonography) to a published VTE diagnostic strategy incorporating assessment of pre-test probability and D-dimer testing.
Methods:
We retrospectively reviewed data from a multicenter diagnostic accuracy study of a D-dimer reagent where consecutive outpatients (n=747) with suspected VTE, including both pulmonary embolism (n=346) and deep venous thrombosis (n=401) were evaluated. By applying a VTE diagnostic strategy and using the proportion of patients that were diagnosed as VTE-negative (n=137 for PE; n=120 for DVT), we developed a cost calculator to compare the average diagnostic test cost per suspected VTE patient, both before and after the implementation of the VTE diagnostic strategy.
Results: Implementation of the VTE diagnostic strategy reduced the average diagnostic test cost for a suspected PE patient by 38% and for a suspected DVT patient by 24%. Assuming the proportion of VTE suspected patients to be 30% PE and 70% DVT, the weighted average reduction in the diagnostic test cost per suspected VTE patient was 32%.
Conclusion:
Implementation of a VTE diagnostic strategy can allow hospitals to reduce costs without compromising patient safety.
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| INTRODUCTION
The cost of healthcare is growing at an unsustainable rate worldwide. 5, 6 implementation in clinical practice is reportedly low. 7 The lack of adoption of these diagnostic strategies is directly associated with increased hospital costs for VTE diagnosis.
Since there can be no compromise on patient safety while cutting costs, hospitals often look for answers by performing cost-minimization analysis, which evaluates 2 established and equally efficacious medical procedures that have the same objective, but differ in their cost burden. This is different than the commonly used cost-effectiveness analysis, which is used to compare relative costs and outcomes in nonmonetary units, such as Quality Adjusted Life Years (QALY). In this study, we report the results of a cost-minimization analysis for the diagnosis of VTE in which standalone imaging is compared to a VTE diagnostic strategy using assay performance data from a previously published multicenter study that evaluated a highly sensitive D-dimer assay. 8 
| MATERIALS AND METHODS

| Study data
The cost-minimization analysis (CMA) was conducted retrospectively using the data obtained from the multicenter evaluation of HemosIL D-Dimer HS 500 (Instrumentation Laboratory, Bedford, MA, USA). 8 The study protocol was designed as a management study to evaluate diagnostic accuracy of a specific D-dimer assay, which required a 3-month follow-up to confirm exclusion of VTE. 
| Imaging tests for VTE
There are multiple imaging tests available for the detection of VTE,
with computed tomography pulmonary angiography (CTPA) preferred for PE, 4 and compression ultrasonography (CUS) for DVT. 9 To maintain the simplicity of the cost calculator we utilized the costs associated with CTPA and CUS as examples in this study.
| Clinical prediction models
To quantify the pretest probability (PTP) of VTE in suspected patients during the multicenter study, the Wells Model (PE 10 and DVT DVT and PE as "low," "moderate," and "high" risk. The VTE diagnostic strategy used in the multicenter study is depicted in Figure 1A ; however, because the study was designed as a diagnostic accuracy study rather than be representative of clinical practice, we retrospectively applied the Clinical & Laboratory Standards Institute (CLSI) VTE diagnostic strategy ( Figure 1B) , 11 which is similar to the recommendation by other professional organizations such as the American College of
Essentials
• A venous thromboembolism (VTE) diagnostic strategy is economical compared to imaging alone.
• Applied a VTE diagnostic strategy to a D-dimer multicenter study for cost-minimization analysis.
• Average diagnostic test costs for patients were significantly lower with a diagnostic strategy.
• Implementation of a VTE diagnostic strategy reduces the diagnostic costs for a hospital.
T A B L E 1 Proportion calculations from multicenter study data Chest Physicians, 9 British Thoracic Society, 5 and British Committee for Standards in Haematology. 6 Using this strategy, all high risk patients (24 for PE, 79 for DVT) would have been sent straight to imaging, whereas all "low" and "moderate" risk patients (322 for PE, 322 for DVT) would have had D-dimer testing performed initially (Table 1) .
| D-dimer assays
D-dimer assays are commonly used in the exclusion of VTE. Using the data from the multicenter study, 137 of suspected PE and 120 of suspected DVT patients with low or moderate PTP were also negative for HemosIL D-Dimer HS 500 (<500 ng/mL Fibrinogen Equivalent Units
[FEU]). These patients were followed three-months later and demonstrated no symptoms of VTE, accounting for a 100% negative predictive value (NPV) (95% CI: 98.6-100%) and 100% sensitivity (95% CI: 95.9-100%) of HemosIL D-Dimer HS 500 in conjunction with a PTP score. 
| Cost-minimization analysis
Using the CLSI recommended VTE diagnostic strategy ( Figure 1B ), two scenarios were created for developing the cost calculator (Table 2) , where the final output was the average diagnostic test cost per suspected VTE patient both before and after the implementation of the VTE diagnostic strategy. In the before scenario, all suspected VTE patients were sent to imaging whereas in the after scenario, only suspected patients that had high PTP or were not excluded by D-dimer testing were referred for imaging.
The cost inputs for imaging and D-dimer tests were obtained from published literature. 12, 13 All monetary amounts used for calculators are reported in US dollars. The average diagnostic test cost per suspected VTE patient in the before scenario was calculated by multiplying 100%, assuming all suspected VTE patients went for imaging, with the imaging costs of CTPA ($648) 12 and CUS ($184) 13 for PE and DVT, respectively.
In the after scenario, the average diagnostic test cost per suspected VTE patient was calculated using weighted averages of the proportion of patients that had low and moderate PTP and went for D-dimer testing ($14), 12 and the proportion of suspected VTE patients that were not excluded after the D-dimer test and went for imaging (Table 1) .
| RESULTS AND DISCUSSION
With the implementation of a VTE Diagnostic Strategy such as the recommendation from CLSI, the total diagnostic test cost per suspected patient was reduced from $648 to $404 (38% reduction)
for PE, and from $184 to $140 (24% reduction) for DVT ( Table 2) .
Assuming the proportion of suspected PE and DVT patients as 30% chose a study that demonstrated no false negative results because if a false negative D-dimer result was identified, a CMA could not have been performed, as the cost of a false negative is assumed to be very high.
Therefore, the implementation of a VTE Diagnostic Strategy incorporating D-dimer testing provides an opportunity for hospitals to effectively reduce the diagnostic test costs for suspected VTE patients without compromising patient safety. In addition to cost savings, patients also benefit by saving the time required for imaging and avoiding unnecessary and potentially harmful radiation. NPV using the multicenter data, the 95% CI lower limit is 98.6% so there is the possibility of a false negative result in a different study population. Finally, as the scope of this study was to perform the cost-minimization analysis, the case for VTE diagnostic strategy can be made stronger by performing cost-effectiveness and cost-utility analysis.
| LIMITATIONS
